Body Surface Gastric Mapping Vs Gastric Emptying Scintigraphy on Clinical Management in Ga
Gastroparesis is a chronic and debilitating gastric disease associated with poor quality of life, psychological distress, frequent hospitalisations, and high healthcare utilization and associated costs. It is defined by persistent upper gastrointestinal symptoms and delayed gastric emptying with no mechanical gastric o
| Condition(s) | Gastroparesis |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Gastroparesis is a chronic and debilitating gastric disease associated with poor quality of life, psychological distress, frequent hospitalisations, and high healthcare utilization and associated costs. It is defined by persistent upper gastrointestinal symptoms and delayed gastric emptying with no mechanical gastric outlet obstruction. Gastric emptying scintigraphy (GES) is the current gold standard for diagnosing gastroparesis but its clinical utility is currently being questioned. Current management strategies have often been found to be ineffective, largely due to an incomplete understanding of the disease's pathophysiology. There is a critical need for more advanced diagnostic testing that can better diagnose patients and guide personalized targeted therapy. Body surface gastric mappi |
| Who can participate | Inclusion Criteria: * Aged over 18 years old * Meeting Rome IV Criteria for Functional Dyspepsia and/or Chronic Nausea and Vomiting Syndrome * Referred for gastric emptying scintigraphy * Normal gastroscopy * Negative or treated H. Pylori status Exclusion Criteria: * Pregnant or breast-feeding * Inability to perform a BSGM test according to Indications for Use: history of severe skin allergies or sensitivity to cosmetics or lotions; chronically damaged or vulnerable epigastric skin (fragile skin, wounds, inflammation); unable to remain in a relaxed reclined position for the test duration. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Western Sydney |
| Locations | Campbelltown, New South Wales, Australia |
| Start date | 2024-05-03 |
| NCT ID | NCT06411574 |
| Official listing | https://clinicaltrials.gov/study/NCT06411574 |